Development of a Non-Human Primate Model of Inhalational Tularemia

FDA Workshop on “Current State and Further Development of Animal Models of Serious Infections Caused by Acinetobacter baumannii and Pseudomonas aeruginosa”

March 1, 2017
Julie A. Hutt, DVM, PhD, Dipl. ACVP
Disclosure Statement: Lovelace is a non-profit organization that performs regulated work for multiple commercial and government sponsors. The work presented herein was funded by NIAID. The speaker has no financial conflicts of interest.
Tularemia

- *F. tularensis subspecies tularensis*-type A strains
- Clinical presentation in humans: glandular, ulceroglandular, oculoglandular, oropharyngeal, pneumonic, typhoidal forms
- Primary pneumonic form after inhalational exposure is the most deadly form
NHP Model Development-Inhalational Tularemia

- No new drugs or vaccines currently under regulatory review, focus is on Animal Model Development and Qualification
- *F. tularensis* subspecies *tularensis*, strain SCHU S4
- Cynomolgus macaques:
  - Historical data in NHPs available from studies conducted in 1940s-1960s
  - Readily available, robust species
  - Sourced from mainland Southeast Asia (not Mauritius)
  - All monkeys screened for pre-existing humoral and cell-mediated immunity to *F. tularensis* prior to assignment to study
NHP Model Development-Inhalational Tularemia

• Approach:
  – Establish LD 50 after head only inhalation exposure to aerosolized SCHU S4
    • Clinical signs, survival, hematology, terminal pathology and microbiology
  – Characterize natural history of disease
    • Telemetry-heart rate, respiratory rate, core body temperature for up to 3 weeks post-challenge
    • Blood for clinical pathology and microbial culture over time in each animal, terminal pathology and culture
    • Serial euthanasia-clinical and anatomic pathology, and microbiology of blood and organs at pre-determined euthanasia time points
LD 50 Study

- 28 male/female cynomolgus macaques, 2-3 yrs of age
- Presented doses from 1.25 to 1.25x10^6 CFU, ~1-3 micron particles; death between day 3 and day 46
- Bacteremia by ~ 3 days post-challenge
- LD 50 < 10 CFU
- Clinical presentation, disease course, time to fever onset and death were dependent upon challenge dose
- Highest doses-rapid death (3 days) with severe bronchopneumonia; clinical signs primarily respiratory
- Lowest doses-survive up to six weeks, with death from disseminated disease; clinical signs primarily anorexia, weight loss, generalized malaise
- Pleuritis; pyogranulomatous to necrotizing lesions in lungs and other organs; variable chronicity; similar to humans
LD50 study: Gross appearance of lungs varied with dose and time to death.
Natural History Studies

– Challenge dose target-1000 CFU
– Challenge dose rationale:
  • Reproducible challenge dose; reproducible disease manifestations and death; survival long enough to be able to evaluate and compare vaccine or therapeutic efficacy
  • Compared efficacy of new vaccine candidates to Live Vaccine Strain (historical data for comparison)
Natural History Studies: Telemetry

- 12 NHPs, measured core body temp, respiratory rate, heart rate
- Loss of diurnal variation of core body temp, and fever onset between 2-3 days; showed decrease in core body temperature near death (later useful as euthanasia criteria)
- Increases in heart and respiratory rate
- Fever onset useful in later antibiotic efficacy studies as trigger to treat criteria
Bacteremia 1st detected on Day 4
Natural History Studies: Serial Pathology

- 16 NHPs, M/F, euthanized 4 each on days 2, 4, 5, 6
- Portal of entry—multiple mucosal surfaces, not just lungs, with some secondary bacterial infections in the nasal cavity
- Local inflammation at site of deposition, followed by inflammation of lymphatic vessels, and draining lymph nodes, and ultimately hematogenous dissemination to macrophage-rich tissues
- Increased WBCs (neutrophils/monocytes) and activation of acute phase response (CRP) between 48 and 72 hrs; increased liver enzymes terminally
NHP Model Development-Inhalational Tularemia

• Challenges/Lessons Learned:
  – Aerosol challenge
    • Well-characterized starting material, *in vitro* growth conditions, and aerosol generation conditions
    • Presented dose is calculated, based on plethysmography—amount deposited and location of deposition vary with breathing rate and depth
    • Particle size influences site of deposition and LD 50
    • Head only challenge allows organism entry from nasal cavity, conjunctiva, oropharynx as well as tracheobronchial tree and deep lung
NHP Model Development-Inhalational Tularemia

• Challenges/Lessons Learned:
  – Telemetry
    • Shallow breathing in NHPs with pleuritis may preclude measurement of respiratory rate
    • SQ temperature chips do not detect fever onset very well
    • HR and RR impacted by human activity in room
  – Prioritize sampling
    • Be cautious that experimental procedures don’t impact disease course-(e.g. Diehl guidelines for blood collection are for healthy animals)
  – Establishment of endpoints is critical
    • Use precise terminology (no “moribund euthanasia” ) and seek input from clinical veterinarian
    • Be consistent in following euthanasia criteria
NHP Model Development-Inhalational Tularemia

• Challenges/Lessons Learned:
  – Collect tissue widely for histopathology—if you don’t look for lesions you likely won’t find them
    • Safety of test article may also be evaluated in disease model
    • Multiple portals of entry identified, which explained variations in clinical presentation, disease course, time to fever/death, and terminal pathology with challenge dose
    • NHPs are not pristine, inbred animals and background lesions/infections may impact outcomes through non-specific immune stimulation
      – Nosocomial Serratia infection in anthrax studies
      – Possible influence of T. cruzi infection on F. tularensis studies
Acknowledgments

Lovelace:
Many, many people-
Technicians
Quality assurance
Study directors
Microbiologists
Immunologists
Clinical veterinarians/surgeons
Aerosol scientists
Physiologists

NIAID:
Patrick Sanz
Tina Guina
Lynda Lanning
Judy Hewitt
Ed Nuzum

University of New Mexico:
Rick Lyons
Terry Wu
Julie Lovchik
Barbara Griffith